The startup develops therapeutic drugs that leverage the ubiquitin-proteasome system to regulate protein levels in the body. This approach targets diseases such as cancer by utilizing natural biological processes for protein degradation.
Funding
$48.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including cancer, are driven by the abnormal accumulation of specific proteins within cells. Traditional drug development approaches often struggle to directly target these disease-causing proteins, particularly when they lack well-defined binding pockets for small-molecule inhibitors. This limitation hinders the development of effective therapies for a wide range of diseases.
Solution
Pin Therapeutics is developing a platform for targeted protein degradation (TPD) that harnesses the ubiquitin-proteasome system (UPS) to selectively remove disease-causing proteins. Their approach utilizes two distinct modalities: PinE3, which employs E3 ligases to tag target proteins for degradation, and PinGLUE, a molecular glue degrader platform that induces proximity between E3 ligases and target proteins. By leveraging these mechanisms, Pin Therapeutics aims to degrade previously "undruggable" proteins, offering a novel therapeutic strategy for various cancers and other diseases. The company is advancing a pipeline of molecular glue degraders and PROTACs targeting solid tumors and blood cancers.
Target Audience
The primary target audience includes patients with cancer and other diseases driven by the accumulation of specific proteins, as well as pharmaceutical companies seeking novel therapeutic strategies for challenging drug targets.
Features
- PinE3 platform utilizing E3 ligases for targeted protein degradation.
- PinGLUE platform employing molecular glue degraders to induce proximity between E3 ligases and target proteins.
- Development of CK1α selective molecular glue degraders for solid and blood tumors.
- PROTAC development targeting specific proteins for degradation in solid tumors.
- Focus on degrading previously "undruggable" proteins.